Behavioral effects and dopamine antagonist properties of N-alkylaminobenzazepines

Drug Development Research

Volumn 37, Issue 1, 1996, Pages 39-47

  Acri, J B ^a   Shah, J H ^a,c   Newman, A H ^a   Belov, Y P ^a,d   Basile, A S ^b   Sharpe, L G ^a   Witkin, J M ^a  

^a NIDA Addiction Research Center   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

Author keywords

Apomorphine; Benzazepines; Cocaine; Dopamine antagonists; Dopamine D1 receptors; Locomotor activity; Mice; Nucleus accumbens; Rats; Stereotypy

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; BENZAZEPINE DERIVATIVE; COCAINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; JHS 271; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TISSUE LEVEL; INTRACEREBRAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029872377     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199601)37:1<39::AID-DDR2>3.0.CO;2-N     Document Type: Article

References (36)

1. Andersen PH, Braestrup C (1986): Evidence for different states of the dopamine D1 receptor: Clozapine and fluperlapine may preferentially label an adenylate cyclase-coupled state of the D1 receptor. J Neurochem 47:1822-1831.
2. 1 dopamine receptor antagonism. Eur J Pharmacol 128:249-253.
3. Cabib S, Castellano C, Cestari V, Filibeck U, Puglisi-Allegra S (1991): D1 and D2 receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse. Psychopharmacology 105:335-339.
4. Chipkin RE, Iorio LC, Coffin VC, McQuade RD, Berger JG, Barnett A (1988): Pharmacological profile of SCH39166: A dopamine D1 selective benzonaphthazine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093-1102.
5. Coffin VL. Latranyi MB, Chipkin RE (1989): Acute extrapyramidal syndrome in cebus monkeys: Development mediated by dopamine D2 but not D1 receptors. J Pharmacol Exp Ther 249:769-774.
6. Coughenour LL, McLean JR, Parker RB (1977): A new device for the rapid measurement of impaired motor function in mice. Pharmacol Biochem Behav 6:351-353.
7. Daly SA, Waddington JL (1992): D-1 dopamine receptors and the topography of unconditioned motor behaviour: Studies with the selective 'full efficacy' benzazepine D-1 agonist SKF 83189. J Psychopharmacol 6:50-60.
8. Derlet RW, Albertson TE, Rice P (1990): The effect of SCH 23390 against toxic doses of cocaine, d-amphetamine and methamphetamine. Life Sci 47:821-827.
9. Finney DJ (1964): Statistical Methods in Biological Assay, 2nd ed. New York: Hafner.
10. Geter-Douglass B, Ailing KL, Acri JB, Witkin JM, Katz JL (1995): Characterization of the behavioral effects of (±)-7-hydroxy-dipropylaminotetralin (7-OH-DPAT). NIDA Research Monograph, Problems of Drug Dependence 153:367.
11. Ginski M, Witkin JM (1994): Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology 114:573-582.
12. Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD (1995): Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxy-dopamine lesioned rat-relationship to circling behaviour. Biochem Pharmacol 49:1185-1193.
13. Goldberg LI (1972): Cardiovascular and renal actions of dopamine: Potential clinical applications. Pharmacol Rev 24:1-29.
14. Hahn RA, Wardell Jr JR, Sarau HM, Ridley PT (1982): Characterization of the peripheral and central effects of SK & F 82526, a novel dopamine receptor agonist. J Pharmacol Exp Ther 223: 305-313.
15. Hieble JP (ed) (1989): Cardiovascular Function of Peripheral Dopamine Receptors. New York: Marcel Dekker.
16. 1 antagonist. Eur J Pharmacol 91:153-154.
17. Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983): SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462-467.
18. 1 dopamine antagonist SCH 23390. Psychopharmacology 95:427-128.
19. Koek W, Colpaert FC (1993): Inhibition of methylphenidate-induced behaviors in rats: Differences among neuroleptics. J Pharmacol Exp Ther 267:181-191.
20. 1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 89:137-141.
21. Litchfield JT, Wilcoxon F (1949): A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 95:99-113.
22. Mailman RB, Schulz DW, Kilts CD, Lewis MH, Rollema H, Wyrick S (1986): The multiplicity of the D1 dopamine receptor. In Breese GR, Creese I (eds): Neurobiology of Central D-1 Receptors. New York: Plenum Press, pp. 53-72.
23. Megens AAHP, Niemegeers CJE. Awouters HL (1992): Antipsychotic profile and side-effect liability of haloperidol, rispeidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats. Drug Dev Res 26:129-145.
24. Meyer ME (1993): Effects of intraacumbens dopamine agonist SKF 38393 and antagonist SCH 23390 on locomotor activities in rats. Pharmacol Biochem Behav 45:843-847.
25. Paxinos G, Watson C (1986): The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press, Inc.
26. Plaznik A, Stefanski R, Kostowski W (1989): Interaction between accumbens D1 and D2 receptors regulating rat locomotor activity. Psychopharmacology 99:558-562.
27. 1 receptors. Med Chem Res 3:574-588.
28. 1 receptor antagonists. J Med Chem 38:4289-4293, 1995.
29. Snedecor GW, Cochran WG (1967): Statistical Methods, 6th ed. Ames, LV: Iowa State University Press, pp. 135-171.
30. Spealman RD (1990): Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers. Psychopharmacology 101:142-145.
31. Tirelli E, Witkin JM (1995): Differential effects of direct and indirect dopamine agonists on the induction of gnawing in C57B1/6J mice. J Pharmacol Exp Ther 237:7-15.
32. Weissman BA, Elson HF, Newman AH (1990): Presence of peripheral benzodiazepine binding sites on primary rat skeletal fibroblast membranes. Eur J Pharmacol 187:369-375.
33. Witkin JM (1994): Pharmacotherapy of cocaine abuse: Preclinical development. Neurosci Biobehav Rev 18:121-142.
34. Witkin JM, Goldberg SR, Katz JL (1989): Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidol. Life Sci 44:1285-1291.
35. Witkin JM, Nichols DE, Terry P, Katz JL (1991): Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J Pharmacol Exp Ther 257:706-713.
36. 1 receptors in the lethal effects of cocaine and a quaternary methiodide analog. J Pharmacol Exp Ther 267:266-274.